Fidelity Investments
MLYS icon

Fidelity Investments’s Mineralys Therapeutics MLYS Stock Holding History

Fidelity Investments’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122M Sell
4,511,689
-349,415
-7% -$9.59M 0.01% 1153
2026
Q1 		$132M Sell
4,861,104
-196,405
-4% -$5.76M 0.01% 1051
2025
Q4 		$184M Buy
5,057,509
+2,986,254
+144% +$120M 0.01% 901
2025
Q3 		$78.5M Buy
2,071,255
+1,766,369
+579% +$38.2M ﹤0.01% 1280
2025
Q2 		$4.13M Buy
304,886
+128
+0% +$1.85K ﹤0.01% 2237
2025
Q1 		$4.84M Buy
304,758
+574
+0.2% +$6.6K ﹤0.01% 2157
2024
Q4 		$3.74M Buy
304,184
+426
+0.1% +$5.57K ﹤0.01% 2256
2024
Q3 		$3.68M Buy
303,758
+32,663
+12% +$395K ﹤0.01% 2217
2024
Q2 		$3.17M Buy
271,095
+269,551
+17,458% +$3.39M ﹤0.01% 2213
2024
Q1 		$19.9K Sell
1,544
-29,743
-95% -$367K ﹤0.01% 4021
2023
Q4 		$269K Sell
31,287
-1,157,366
-97% -$9.09M ﹤0.01% 2863
2023
Q3 		$11.3M Buy
1,188,653
+457,815
+63% +$5.97M ﹤0.01% 1790
2023
Q2 		$12.5M Buy
730,838
+730,209
+116,090% +$10.9M ﹤0.01% 1791
2023
Q1 		$9.85K Buy
+629
New +$10.6K ﹤0.01% 4136

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments's MLYS Position: Q2 2026 in Review

Fidelity Investments reduced its Mineralys Therapeutics (MLYS) stake by 7.2% in Q2 2026, selling an estimated $9.59M and leaving 4,511,689 shares worth $122M. The position accounts for 0.01% of the portfolio, ranked #1153.

Fidelity Investments first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $184M in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Fidelity Investments held 4,511,689 shares of Mineralys Therapeutics worth $122M as of Q2 2026.
  • Fidelity Investments sold 349,415 Mineralys Therapeutics shares in Q2 2026, an estimated $9.59M.
  • Mineralys Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #1153 holding.
  • Fidelity Investments first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Fidelity Investments's Mineralys Therapeutics position peaked at $184M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.